WU-CART-007 is under clinical development by Wugen and currently in Phase II for Lymphoblastic Lymphoma. According to GlobalData, Phase II drugs for Lymphoblastic Lymphoma have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how WU-CART-007’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

WU-CART-007 overview

WU-CART-007 is under development for the treatment of recurrent and refractory T-cell acute lymphocytic leukemia and lymphoblastic lymphoma (LBL). The therapy constitutes of genetically manipulated universal allogeneic T cells which express a chimeric antigen receptor that is transduced by lentivirus. It targets cells expressing T cell antigen CD7 and is developed based on off-the-shelf fratricide-resistant CAR-T platform. It was also under development for the treatment of acute myeloblastic leukemia and non-Hodgkin lymphoma.. It is administered through intravenous route.

Wugen overview

Wugen is a biotechnology company that develops cell therapies for treatment of hematologic cancer and other solid tumors. The company is investigating its lead product candidate WU-NK-101, an allogenic off-the-shelf NK cell therapy for treatment of acute myeloid leukemia (AML); and monoclonal antibodies (mAb) to treat other solid tumors. It is also developing an off-the shelf fratricide-resistant CAR T cell therapy candidate, WU-CART-007 for treating T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (LBL); and WU-NK-201, a memory NK cell therapy for treatment of solid tumors. The company was funded by Aisling Capital, RiverVest Ventures, Velosity Capital Management, LYZZ Capital, BioGenerator, and others. Wugen is headquartered in St. Louis, Missouri, the US.

For a complete picture of WU-CART-007’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.